Gossamer Bio CEO Faheem Hasnain at #BIO22 (J.T. MacMillan Photography)
Gossamer lays off 25% of employees, cuts all programs except PAH drug
As Gossamer Bio goes all in on its lead drug for pulmonary arterial hypertension (PAH), it’s cutting off all other clinical and preclinical programs — as well as 25% of its staff.
Faheem Hasnain, the co-founder, CEO and chair of Gossamer, called the restructuring decision difficult in a press release but “a necessary step to focus the organization on activities which maximize the potential of seralutinib,” the PAH candidate.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters